Bioequivalence and Bioavailability Forum 09:19 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

What's the problem? [Regulatives / Guidelines]

posted by nobody - 2017-05-17 09:31  - Posting: # 17364
Views: 11,735

PS: No, I don't think that assay performance will do anything to intraindiv. CV of a drug product, as long as

- not practically all samples are around LLOQ
- effects are not random.

Did some sims in the old daysTM, effect of assay when validated according to current recommendations is negligible.

Especially for the "11% CV in 5 other trials, suddenly 40% in my trial" example there is no explanation remotely related to assay.

Kindest regards, nobody

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,782 posts in 4,002 threads, 1,260 registered users;
online 16 (0 registered, 16 guests [including 13 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed